KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Income from Continuing Operations (2020 - 2025)

Recursion Pharmaceuticals' Income from Continuing Operations history spans 6 years, with the latest figure at 108122000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 39.56% year-over-year to 108122000.0; the TTM value through Dec 2025 reached 644759000.0, down 39.06%, while the annual FY2025 figure was 644759000.0, 39.06% down from the prior year.
  • Income from Continuing Operations reached 108122000.0 in Q4 2025 per RXRX's latest filing, up from 162253000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 30484000.0 in Q1 2021 to a low of 202487000.0 in Q1 2025.
  • Average Income from Continuing Operations over 5 years is 93249400.0, with a median of 84049500.0 recorded in 2023.
  • Peak YoY movement for Income from Continuing Operations: tumbled 153.94% in 2021, then soared 39.56% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 64960000.0 in 2021, then increased by 6.12% to 60982000.0 in 2022, then tumbled by 52.5% to 92996000.0 in 2023, then tumbled by 92.38% to 178906000.0 in 2024, then soared by 39.56% to 108122000.0 in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Income from Continuing Operations are 108122000.0 (Q4 2025), 162253000.0 (Q3 2025), and 171897000.0 (Q2 2025).